CooperVision Acquires No7 Contact Lenses to
Expand Specialty EyeCare Business
Establishes Direct-to-ECP Presence in the UK, Extends Commitment to
Growing Myopia Management and Irregular Cornea Solutions
FAREHAM, United Kingdom, 27th April 2021—CooperVision today announced its acquisition of No7 Contact Lenses, which designs and manufactures specialty contact lenses distributed primarily in the United Kingdom. The company will operate within the CooperVision Specialty EyeCare group, complementing a portfolio of innovative products used by eye care professionals to manage challenges such as myopia progression in children and irregular cornea.
“No7 Contact Lenses has been our partner for several years in the UK while expanding its business. The acquisition will enable us to directly offer more of our products through No7’s well-established channels, while expanding access to their designs,” said Juan Carlos Aragón, OD, President of CooperVision Specialty EyeCare. “In tandem, the agreement should further accelerate the development of myopia management solutions in the UK.”
“We have great respect for CooperVision and have enjoyed a strong working relationship with its Specialty Eyecare team,” said Ashley Pepper, Managing Director of No7 Contact Lenses. “Today’s news will help us have an even greater impact on the eye care professionals who prescribe our contact lenses, and the adults and children whose vision and lives are made better because of them.”
CooperVision Specialty EyeCare develops, manufacturers, and provides worldwide access to a portfolio of industry leading soft custom and rigid gas permeable contact lens designs to address myopia management, irregular cornea management and presbyopia management. Its steady voice, ongoing research and innovative products and services play a leading role in expanding care worldwide. The group’s other brands include Blanchard, GP Specialists, Paragon, Procornea and Soflex.
No7 customers should continue to work with their current representatives and follow established ordering and support processes.
Terms of the transaction were not disclosed.
# # #
About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses worldwide. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Media Contact
Mike McDougall, APR, Fellow PRSA, McDougall Communications
mike@mcdougallpr.com or +1-585-434-2150